Docetaxel Enhances the Expression of STING Protein in PC3 Cells, and cGAMP Attenuates this Effect
Novelty in Biomedicine,
Vol. 8 No. 4 (2020),
29 November 2020
,
Page 196-204
https://doi.org/10.22037/nbm.v8i4.30845
Abstract
Background: The stimulator of interferon genes (STING) agonist (cGAMP) kills the cancer cells through the activation of the innate immune system. PC3 cells are high in BTK and low in STING. In this study, the effect of adding STING agonist, cGAMP, to docetaxel investigated.Materials and Methods: PC3 cells were treated with docetaxel, cGAMP, and a combination of the docetaxel and cGAMP. Cell toxicity was evaluated by MTT assay, and changes of STING, IRF3, BTK, and DDX41 genes’ expression were quantified by the real-time PCR. STING protein was also detected by Western blotting.
Results: The IC50 of docetaxel was 31.1 nM, and cGAMP did not change it significantly but decreased docetaxel toxicity about 30%. Docetaxel increased IRF3, BTK, and DDX41 gene expression significantly, and STING protein about 5 folds. By adding cGAMP to docetaxel STING, IRF3, and BTK, expression decreased several folds.
Conclusion: In this in vitro study, cGAMP potentiated docetaxel’s effects and alleviated it.
- Docetaxel; cGAMP; PC3; Interferon; STING; Prostate Cancer
How to Cite
References
Eigl BJ, Chi K, Tu D, Hotte SJ, Winquist E, Booth CM, et al. A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209. 2018;9(8):8155.
Stenner F, Rothschild SI, Betticher D, Caspar C, Morant R, Popescu R, et al. Quality of Life in Second-Line Treatment of Metastatic Castration-Resistant Prostate Cancer Using Cabazitaxel or Other Therapies After Previous Docetaxel Chemotherapy: Swiss Observational Treatment Registry. 2018;16(1):e151-e9.
Barber GNJNRI. STING: infection, inflammation and cancer. 2015;15(12):760.
Cai X, Chiu Y-H, Chen ZJJMc. The cGAS-cGAMP-STING pathway of cytosolic DNA sensing and signaling. 2014;54(2):289-96.
Corrales L, Gajewski TF. Molecular pathways: targeting the stimulator of interferon genes (STING) in the immunotherapy of cancer. Clinical Cancer Research. 2015;21(21):4774-9.
Sun L, Wu J, Du F, Chen X, Chen ZJ. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science. 2013;339(6121):786-91.
Surpris G, Poltorak A. The expanding regulatory network of STING-mediated signaling. Current opinion in microbiology. 2016;32:144-50.
Wu J, Sun L, Chen X, Du F, Shi H, Chen C, et al. Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science. 2013;339(6121):826-30.
Corrales L, Glickman LH, McWhirter SM, Kanne DB, Sivick KE, Katibah GE, et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell reports. 2015;11(7):1018-30.
Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity. 2014;41(5):843-52.
Ho SS, Zhang WY, Tan NYJ, Khatoo M, Suter MA, Tripathi S, et al. The DNA structure-specific endonuclease MUS81 mediates DNA sensor STING-dependent host rejection of prostate cancer cells. Immunity. 2016;44(5):1177-89.
Ishikawa H, Barber GN. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature. 2008;455(7213):674.
McPherson JP, Lemmers B, Chahwan R, Pamidi A, Migon E, Matysiak-Zablocki E, et al. Involvement of mammalian Mus81 in genome integrity and tumor suppression. Science. 2004;304(5678):1822-6.
Nakamura T, Miyabe H, Hyodo M, Sato Y, Hayakawa Y, Harashima H. Liposomes loaded with a STING pathway ligand, cyclic di-GMP, enhance cancer immunotherapy against metastatic melanoma. Journal of controlled release. 2015;216:149-57.
Ohkuri T, Ghosh A, Kosaka A, Zhu J, Ikeura M, David M, et al. STING contributes to anti-glioma immunity via triggering type-I IFN signals in the tumor microenvironment. Journal for immunotherapy of cancer. 2014;2(3):P228.
Woo S-R, Corrales L, Gajewski TF. Innate immune recognition of cancer. Annual review of immunology. 2015;33:445-74.
Xia T, Konno H, Ahn J, Barber GN. Deregulation of STING signaling in colorectal carcinoma constrains DNA damage responses and correlates with tumorigenesis. Cell reports. 2016;14(2):282-97.
Xia T, Konno H, Barber GN. Recurrent loss of STING signaling in melanoma correlates with susceptibility to viral oncolysis. Cancer research. 2016;76(22):6747-59.
Zhu Q, Man SM, Gurung P, Liu Z, Vogel P, Lamkanfi M, et al. Cutting edge: STING mediates protection against colorectal tumorigenesis by governing the magnitude of intestinal inflammation. The Journal of Immunology. 2014;193(10):4779-82.
Gao L, Liu H, Sun X, Gao D, Zhang C, Jia B, et al. Molecular imaging of post-Src inhibition tumor signatures for guiding dasatinib combination therapy. 2016;57(2):321-6.
James N, Mason MJJCO. Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: first survival results from STAMPEDE. 2015;33(33):5001.
Quinn DI, Tangen CM, Hussain M, Lara Jr PN, Goldkorn A, Moinpour CM, et al. Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. 2013;14(9):893-900.
Chandra D, Quispe-Tintaya W, Jahangir A, Asafu-Adjei D, Ramos I, Sintim HO, et al. STING ligand c-di-GMP improves cancer vaccination against metastatic breast cancer. Cancer immunology research. 2014;2(9):901-10.
Li T, Cheng H, Yuan H, Xu Q, Shu C, Zhang Y, et al. Antitumor activity of cGAMP via stimulation of cGAS-cGAMP-STING-IRF3 mediated innate immune response. 2016;6:19049.
Burdette DL, Monroe KM, Sotelo-Troha K, Iwig JS, Eckert B, Hyodo M, et al. STING is a direct innate immune sensor of cyclic di-GMP. Nature. 2011;478(7370):515.
Opoku-Temeng C, Zhou J, Zheng Y, Su J, Sintim HO. Cyclic dinucleotide (c-di-GMP, c-di-AMP, and cGAMP) signalings have come of age to be inhibited by small molecules. Chemical Communications. 2016;52(60):9327-42.
Schaap P. Cyclic di‐nucleotide signaling enters the eukaryote domain. IUBMB life. 2013;65(11):897-903.
Sokolowska O, Nowis D. STING Signaling in Cancer Cells: Important or Not? Archivum immunologiae et therapiae experimentalis. 2018;66(2):125-32.
Chawla-Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, Silverman RH, et al. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis : an international journal on programmed cell death. 2003;8(3):237-49.
Ran Y, Shu HB, Wang YY. MITA/STING: a central and multifaceted mediator in innate immune response. Cytokine Growth Factor Rev. 2014;25(6):631-9.
Tanaka Y, Chen ZJ. STING specifies IRF3 phosphorylation by TBK1 in the cytosolic DNA signaling pathway. Sci Signal. 2012;5(214):ra20.
Gravekamp C, Chandra D. Targeting STING pathways for the treatment of cancer. Oncoimmunology. 2015;4(12):e988463.
Xiangshi T, Li T, Xu Q, Pan J, Rui Y, Cheng H, et al. Antitumor use of cyclic dinucleotide cgmp. Google Patents; 2017.
Tang CH, Zundell JA, Ranatunga S, Lin C, Nefedova Y, Del Valle JR, et al. Agonist-Mediated Activation of STING Induces Apoptosis in Malignant B Cells. Cancer Res. 2016;76(8):2137-52.
Watson RO, Bell SL, MacDuff DA, Kimmey JM, Diner EJ, Olivas J, et al. The Cytosolic Sensor cGAS Detects Mycobacterium tuberculosis DNA to Induce Type I Interferons and Activate Autophagy. Cell Host Microbe. 2015;17(6):811-9.
Demaria O, De Gassart A, Coso S, Gestermann N, Di Domizio J, Flatz L, et al. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity. Proceedings of the National Academy of Sciences. 2015;112(50):15408-13.
Ahn J, Xia T, Konno H, Konno K, Ruiz P, Barber GN. Inflammation-driven carcinogenesis is mediated through STING. Nature communications. 2014;5:5166.
Ng KW, Marshall EA, Bell JC, Lam WLJTii. cGAS–STING and cancer: dichotomous roles in tumor immunity and development. 2018;39(1):44-54.
Guo W, Liu R, Bhardwaj G, Yang JC, Changou C, Ma AH, et al. Targeting Btk/Etk of prostate cancer cells by a novel dual inhibitor. Cell death & disease. 2014;5:e1409.
Lee KG, Kim SS, Kui L, Voon DC, Mauduit M, Bist P, et al. Bruton's tyrosine kinase phosphorylates DDX41 and activates its binding of dsDNA and STING to initiate type 1 interferon response. Cell Rep. 2015;10(7):1055-65.
He L, Xiao X, Yang X, Zhang Z, Wu L, Liu ZJCl. STING signaling in tumorigenesis and cancer therapy: A friend or foe? 2017;402:203-12.
Bhatelia K, Singh A, Tomar D, Singh K, Sripada L, Chagtoo M, et al. Antiviral signaling protein MITA acts as a tumor suppressor in breast cancer by regulating NF-κB induced cell death. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2014;1842(2):144-53.
Song S, Peng P, Tang Z, Zhao J, Wu W, Li H, et al. Decreased expression of STING predicts poor prognosis in patients with gastric cancer. 2017;7:39858.
Bose DJIjoms. cGAS/STING pathway in cancer: Jekyll and Hyde story of cancer immune response. 2017;18(11):2456.
Chen Q, Sun L, Chen ZJ. Regulation and function of the cGAS–STING pathway of cytosolic DNA sensing. Nature immunology. 2016;17(10):1142.
Corrales L, McWhirter SM, Dubensky TW, Gajewski TF. The host STING pathway at the interface of cancer and immunity. The Journal of clinical investigation. 2016;126(7):2404-11.
Ma F, Li B, Liu SY, Iyer SS, Yu Y, Wu A, et al. Positive feedback regulation of type I IFN production by the IFN-inducible DNA sensor cGAS. J Immunol. 2015;194(4):1545-54.
Ma F, Li B, Yu Y, Iyer SS, Sun M, Cheng G. Positive feedback regulation of type I interferon by the interferon-stimulated gene STING. EMBO Rep. 2015;16(2):202-12.
Schoggins JW, MacDuff DA, Imanaka N, Gainey MD, Shrestha B, Eitson JL, et al. Pan-viral specificity of IFN-induced genes reveals new roles for cGAS in innate immunity. Nature. 2014;505(7485):691-5.
Konno H, Konno K, Barber GN. Cyclic dinucleotides trigger ULK1 (ATG1) phosphorylation of STING to prevent sustained innate immune signaling. Cell. 2013;155(3):688-98.
Wang Y, Lian Q, Yang B, Yan S, Zhou H, He L, et al. TRIM30alpha Is a Negative-Feedback Regulator of the Intracellular DNA and DNA Virus-Triggered Response by Targeting STING. PLoS Pathog. 2015;11(6):e1005012.
Zhong B, Zhang L, Lei C, Li Y, Mao AP, Yang Y, et al. The ubiquitin ligase RNF5 regulates antiviral responses by mediating degradation of the adaptor protein MITA. Immunity. 2009;30(3):397-407.
Rodero MP, Crow YJ. cGMP-AMP synthase paves the way to autoimmunity. Proc Natl Acad Sci U S A. 2015;112(42):12903-4.
- Abstract Viewed: 406 times
- PDF Downloaded: 3077 times